<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835510</url>
  </required_header>
  <id_info>
    <org_study_id>BTNF-0708</org_study_id>
    <nct_id>NCT00835510</nct_id>
  </id_info>
  <brief_title>Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine
      hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in
      the treatment of interdigital tinea pedis, and to show the superiority of the active
      treatments over that of the placebo (vehicle).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Cure - Superiority Analysis</measure>
    <time_frame>42 days</time_frame>
    <description>Therapeutic Cure requires both Clinical Cure and Mycological Cure.
Clinical Cure was based on the following signs and symptoms: fissuring, erythema, maceration, vesiculation, scaling, exudation, pruritus, burning. Each clinical symptom was evaluated using a 0-3 point rating scale: none=0, mild=1, moderate=2 or severe=3. If the score for erythema was ≤ 2 and the sum for all of the other 7 signs and symptoms was &lt;2 then the patient was considered a Clinical Cure.
Mycological Cure: The potassium hydroxide (KOH) and the fungal culture were both negative.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic Cure Non-Inferiority Comparison of Butenafine Cream and Lotrimin Ultra</measure>
    <time_frame>42 days</time_frame>
    <description>Patient was cured both by symptoms (Clinical Cure) and by the results of fungal testing (Mycological Cure).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Cure</measure>
    <time_frame>7 days</time_frame>
    <description>Subject with clinical and mycological cure at day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycologic Cure</measure>
    <time_frame>42 days</time_frame>
    <description>Negative KOH and fungal culture at day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>42 days</time_frame>
    <description>The following 8 signs and symptoms are rated at each visit:
Erythema Fissuring Maceration Vesiculation Desquamation/scaling Exudation Pruritus Stinging/Burning
Each symptom is evaluated using the following scale:
0 = None- Complete absence of any sign or symptom
= Mild - obvious but minimal involvement
= Moderate - something that is easily noted
= Severe - quite marked
Clinical cure is defined as a score of 2 (moderate) or less for erythema and a total score for seven other signs and symptoms less than 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Adverse Event Profile</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">548</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Butenafine cream 1% (Taro)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Butenafine cream manufactured by Taro applied for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrimin Ultra (butenafine) 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Butenafine vehicle applied for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butenafine cream 1% manufactured by Taro</intervention_name>
    <description>Treatment applied to affected area twice daily for 7 days</description>
    <arm_group_label>Butenafine cream 1% (Taro)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lotrimin Ultra (butenafine) 1%</intervention_name>
    <description>Treatment applied to affected area twice daily for 7 days</description>
    <arm_group_label>Lotrimin Ultra (butenafine) 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butenafine Vehicle manufactured by Taro</intervention_name>
    <description>Treatment applied to affected area twice daily for 7 days</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Microbiologically confirmed clinical diagnosis of interdigital tinea pedis

          -  If female and of child bearing potential, prepare to abstain from sexual intercourse
             or use a reliable method of contraception during the study (e.g., condom,
             intra-uterine device (IUD), oral, transdermal, injected or implanted hormonal
             contraceptives).

          -  A confirmed clinical diagnosis of interdigital tinea pedis. Lesions are to be
             predominately interdigital but may extend to other areas of the foot (the
             non-interdigital lesions must not be hyperkeratotic).

          -  The presence of tinea pedis infection, confirmed by the observation of segmented
             fungal hyphae during a microscopic potassium hydroxide (KOH) wet mount examination
             (potassium hydroxide mount preparation).

          -  Identification of an appropriate dermatophyte by culture sent to the central
             laboratory. The appropriate dermatophytes are Trichophyton rubrum, Trichophyton
             mentagrophyte or Epidermophyton floccosum.

        Exclusion Criteria:

          -  Use of any of the following within the indicated timeline:

          -  Oral or injectable steroids

          -  Any oral anti-fungals within 4 weeks of the study start

          -  Use of topical corticosteroids or any other topical antipruritics on the feet within
             72 hours of the study start.

          -  Any prescription or over-the-counter (OTC) topical antifungals on the feet within two
             weeks prior to study entry

          -  Use of any antihistamines within 72 hours of the study start.

          -  Any known hypersensitivity to butenafine or other antifungal agents.

          -  Evidence of any concurrent dermatophytic infection of toe nails (onychomycosis) or
             other dermatological condition of the foot that may interfere with the Investigator's
             evaluation of tinea pedis.

          -  Patients with recurrent tinea pedis (more than 3 infections in the past 12 months) who
             have been unresponsive to previous antifungal therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Martinez</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Belize City</city>
        <country>Belize</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belize</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>May 4, 2009</results_first_submitted>
  <results_first_submitted_qc>September 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2009</results_first_posted>
  <last_update_submitted>January 2, 2014</last_update_submitted>
  <last_update_submitted_qc>January 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea pedis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Butenafine</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients 12 years of age and older, who presented with interdigital tinea pedis, with a positive potassium hydroxide test (KOH) and met the inclusion/exclusion criteria were enrolled in the trial. Subsequently samples were sent for culture to confirm that either T. rubrum, T. mentagrophytes, or E. floccosum were the causative organism.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Butenafine Cream 1% (Taro)</title>
          <description>Butenafine cream manufactured by Taro applied for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Lotrimin Ultra (Butenafine) 1%</title>
          <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
        </group>
        <group group_id="P3">
          <title>Vehicle</title>
          <description>Butenafine vehicle applied for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Positive Fungal Culture</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Butenafine Cream 1% (Taro)</title>
          <description>Butenafine cream manufactured by Taro applied for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Lotrimin Ultra (Butenafine) 1%</title>
          <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Vehicle</title>
          <description>Butenafine vehicle applied for 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="149"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="375"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belize</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Cure - Superiority Analysis</title>
        <description>Therapeutic Cure requires both Clinical Cure and Mycological Cure.
Clinical Cure was based on the following signs and symptoms: fissuring, erythema, maceration, vesiculation, scaling, exudation, pruritus, burning. Each clinical symptom was evaluated using a 0-3 point rating scale: none=0, mild=1, moderate=2 or severe=3. If the score for erythema was ≤ 2 and the sum for all of the other 7 signs and symptoms was &lt;2 then the patient was considered a Clinical Cure.
Mycological Cure: The potassium hydroxide (KOH) and the fungal culture were both negative.</description>
        <time_frame>42 days</time_frame>
        <population>Patients with negative cultures at baseline are excluded. Efficacy ITT analysis includes all patients with positive baseline cultures, who received at least one dose of medication, had a follow-up visit and had data for the day 42 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Butenafine Cream 1% (Taro)</title>
            <description>Butenafine cream manufactured by Taro applied for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Lotrimin Ultra (Butenafine) 1%</title>
            <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Butenafine vehicle applied for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Cure - Superiority Analysis</title>
          <description>Therapeutic Cure requires both Clinical Cure and Mycological Cure.
Clinical Cure was based on the following signs and symptoms: fissuring, erythema, maceration, vesiculation, scaling, exudation, pruritus, burning. Each clinical symptom was evaluated using a 0-3 point rating scale: none=0, mild=1, moderate=2 or severe=3. If the score for erythema was ≤ 2 and the sum for all of the other 7 signs and symptoms was &lt;2 then the patient was considered a Clinical Cure.
Mycological Cure: The potassium hydroxide (KOH) and the fungal culture were both negative.</description>
          <population>Patients with negative cultures at baseline are excluded. Efficacy ITT analysis includes all patients with positive baseline cultures, who received at least one dose of medication, had a follow-up visit and had data for the day 42 visit.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0127</p_value>
            <method>Fisher Exact</method>
            <method_desc>two-sided</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <method_desc>two-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Therapeutic Cure</title>
        <description>Subject with clinical and mycological cure at day 7</description>
        <time_frame>7 days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Butenafine Cream 1% (Taro)</title>
            <description>Butenafine cream manufactured by Taro applied for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Lotrimin Ultra (Butenafine) 1%</title>
            <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Butenafine vehicle applied for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Cure</title>
          <description>Subject with clinical and mycological cure at day 7</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycologic Cure</title>
        <description>Negative KOH and fungal culture at day 42</description>
        <time_frame>42 days</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Butenafine Cream 1% (Taro)</title>
            <description>Butenafine cream manufactured by Taro applied for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Lotrimin Ultra (Butenafine) 1%</title>
            <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Butenafine vehicle applied for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mycologic Cure</title>
          <description>Negative KOH and fungal culture at day 42</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="128"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cure</title>
        <description>The following 8 signs and symptoms are rated at each visit:
Erythema Fissuring Maceration Vesiculation Desquamation/scaling Exudation Pruritus Stinging/Burning
Each symptom is evaluated using the following scale:
0 = None- Complete absence of any sign or symptom
= Mild – obvious but minimal involvement
= Moderate – something that is easily noted
= Severe – quite marked
Clinical cure is defined as a score of 2 (moderate) or less for erythema and a total score for seven other signs and symptoms less than 2.</description>
        <time_frame>42 days</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Butenafine Cream 1% (Taro)</title>
            <description>Butenafine cream manufactured by Taro applied for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Lotrimin Ultra (Butenafine) 1%</title>
            <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Butenafine vehicle applied for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure</title>
          <description>The following 8 signs and symptoms are rated at each visit:
Erythema Fissuring Maceration Vesiculation Desquamation/scaling Exudation Pruritus Stinging/Burning
Each symptom is evaluated using the following scale:
0 = None- Complete absence of any sign or symptom
= Mild – obvious but minimal involvement
= Moderate – something that is easily noted
= Severe – quite marked
Clinical cure is defined as a score of 2 (moderate) or less for erythema and a total score for seven other signs and symptoms less than 2.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Adverse Event Profile</title>
        <time_frame>42 days</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Cure Non-Inferiority Comparison of Butenafine Cream and Lotrimin Ultra</title>
        <description>Patient was cured both by symptoms (Clinical Cure) and by the results of fungal testing (Mycological Cure).</description>
        <time_frame>42 days</time_frame>
        <population>Patients with negative cultures excluded. Use per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Butenafine Cream 1% (Taro)</title>
            <description>Butenafine cream manufactured by Taro applied for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Lotrimin Ultra (Butenafine) 1%</title>
            <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>Butenafine vehicle applied for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Cure Non-Inferiority Comparison of Butenafine Cream and Lotrimin Ultra</title>
          <description>Patient was cured both by symptoms (Clinical Cure) and by the results of fungal testing (Mycological Cure).</description>
          <population>Patients with negative cultures excluded. Use per protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="139"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The criteria for equivalence is that the 90% confidence interval for the difference in cure rate had to be between -20% to +20%.</non_inferiority_desc>
            <param_type>Cure rate difference</param_type>
            <param_value>-19.78</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>-30.27</ci_lower_limit>
            <ci_upper_limit>-9.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the 42 day duration of the study.</time_frame>
      <desc>The Safety Population includes all 548 patients who received at least a single dose of medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Butenafine Cream 1% (Taro)</title>
          <description>Butenafine cream manufactured by Taro applied for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Lotrimin Ultra (Butenafine) 1%</title>
          <description>Lotrimin Ultra (butenafine) applied for 7 days</description>
        </group>
        <group group_id="E3">
          <title>Vehicle</title>
          <description>Butenafine vehicle applied for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14"/>
                <counts group_id="E2" subjects_affected="21"/>
                <counts group_id="E3" subjects_affected="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="221"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Taro Pharmaceuticals</organization>
      <phone>(914) 345-9001 ext 6427</phone>
      <email>medical.affairs@taro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

